GenMark placed 65 ePlex analyzers in Q3, the first full quarter after the platform's launch in the US, and it expects to exit 2017 with up to 200 placements.
The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.
Results from a randomized clinical trial known as GIFT suggest that genotype-guided warfarin dosing is linked to fewer adverse events than clinical dosing.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
Going forward, the company will focus more on the global commercialization of its ePlex system and menu expansion.
The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.
With CE marking for the gram-positive and gram-negative panels, the firm has achieved the designation for its family of three ePlex bloodstream infection assays.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
After announcing a $65 million public offering on Monday to fund commercialization efforts, the firm has increased the expected proceeds to $75 million.
The firm said that it intends to use the net proceeds from the offering for general corporate purposes and to fund its commercialization efforts.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.